Publications by authors named "L Max Laban-Seminario"
Article Synopsis
- * A study was conducted to analyze the availability of massive online open courses (MOOCs) in biomedical informatics, finding 1333 total courses, with 79 specifically related to health informatics.
- * The majority of these courses are offered through Coursera and mainly by U.S. institutions, focusing on areas like translational bioinformatics and public health informatics, which can help train more professionals globally.
Background: Peru faces challenges to provide adequate care to stroke patients. Length of hospitalization and in-hospital mortality are two well-known indicators of stroke care. We aimed to describe the length of stay (LOS) of stroke in Peru, and to assess in-hospital mortality risk due to stroke, and subtypes.
View Article and Find Full Text PDFDigital health refers to the use of novel information com-munication technologies in healthcare. The use of these technologies could positively impact public health and health outcomes of populations by generating timely data, and facili-tating the process of data collection, analysis, and knowledge translation. Using selected case studies, we aim to describe the opportunities and barriers in the use of technology applied to health-related research.
View Article and Find Full Text PDFObjective: To characterize diabetes care across healthcare facilities in six Peruvian regions.
Methods: Cross-sectional study of patients with type 2 diabetes mellitus (T2DM), ranging from primary care facilities to hospital-based facilities, in six Peruvian regions. Data was collected by health staff trained between 2012 and 2016.
Efficacy and Safety in the Continued Treatment With a Biosimilar Drug in Patients Receiving Infliximab: A Systematic Review in the Context of Decision-Making From a Latin-American Country.
Front Pharmacol
November 2019
Biological products, including infliximab (INF), are a therapeutic option for various medical conditions. In the Peruvian Social Security (EsSalud), infliximab is approved for the treatment of rheumatoid arthritis, psoriasis, psoriatic arthropathy, ankylosing spondylitis, ulcerative colitis and Crohn's disease (in cases refractory to conventional treatment). Biosimilars are a safe and effective alternative approved for these diseases in patients who start treatment with infliximab.
View Article and Find Full Text PDF